Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Theory of Literature
$243.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Painful Sex Associated with Menopause: Interpreting FDA Warnings when Choosing a Treatment for Dyspareunia
Tell A Friend
 
Tell someone you know about this product.
Painful Sex Associated with Menopause: Interpreting FDA Warnings when Choosing a Treatment for Dyspareunia
Retail Price: $205.00
10% Online Discount
You Pay:

$184.50
Authors: Michael W. DeGregorio, Timothy B. Cadman and Gregory T. Wurz (University of California, Davis Department of Internal Medicine, Division of Hematology and Oncology, CA, US) 
Book Description:
Dyspareunia, or painful sexual intercourse, associated with menopause has been a taboo subject for decades. During the past year, postmenopausal women have been saturated with print and television advertisements regarding two prescription treatments for painful sex associated with menopause. This book is intended to elucidate in understandable terms the two prescription options currently available for the treatment of dyspareunia, Premarin® (conjugated equine estrogens) Vaginal Cream and Osphena™ (ospemifene) oral tablets. Premarin® is a cocktail of hormones isolated from the urine of pregnant horses that was originally approved by the U.S. Food and Drug Administration (FDA) for the treatment of menopausal symptoms in 1942. Today, Premarin® remains the most commonly prescribed hormone replacement therapy (HRT). Osphena™ is a synthetic non-estrogen drug approved in 2013 that is classified as a selective estrogen receptor modulator (SERM). Other SERMs approved by the FDA include tamoxifen for breast cancer treatment and prevention, and Evista® (raloxifene) for the prevention of postmenopausal osteoporosis and reducing the risk of breast cancer. The FDA is required to educate the public about the benefits and risks of prescription drugs. Unfortunately, these messages are not always clear. We discuss, in understandable terms, the benefits and risks of Premarin® Vaginal Cream and Osphena™ oral tablets as seen in media advertisements, boxed warnings and package inserts. Throughout this book, we discuss the history of these two treatment options for dyspareunia and the future research intended to improve upon hormone replacement therapy for postmenopausal women. (Imprint: Nova Biomedical)

Table of Contents:
About the Authors pp.vii-viii

Preface pp.ix-xi

Chapter 1: Quality of Life Impacts of Vulvar and Vaginal Atrophy (VVA) and Other Menopausal Symptoms pp.1-26

Chapter 2: Interpreting Television Commercials pp.27-38

Chapter 3: Premarin®: History and Development of Hormone Replacement
Therapy (HRT)pp.39-68

Chapter 4: Osphena™ (Ospemifene): History, Development and FDA Approval of a Non-Estrogen pp.69-108

Chapter 5: Understanding Side Effects: Boxed Warnings and Package Inserts pp.109-128

Chapter 6: What Are the Effects of Osphena™ on Bone?pp. 129-146

Chapter 7: What are the Effects of Osphena™ in the Breast? pp.147-166

Glossary of Terms pp.167-182

Index pp.183-191



   Series:
      Sexology Research and Issues
   Binding: Hardcover
   Pub. Date: 2014 - 4th Quarter
   Pages: 202. 6x9 - (NBC-C)
   ISBN: 978-1-63321-929-8
   Status: AV
  
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
  
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2020

Painful Sex Associated with Menopause: Interpreting FDA Warnings when Choosing a Treatment for Dyspareunia